These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3488924)

  • 41. Monoclonal antibody against human interleukin 2 (IL 2). I. Purification of IL 2 for the production of monoclonal antibodies.
    Stadler BM; Berenstein EH; Siraganian RP; Oppenheim JJ
    J Immunol; 1982 Apr; 128(4):1620-4. PubMed ID: 6977565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant tumor necrosis factor alpha inhibits growth of methylcholanthrene-induced sarcoma and enhances natural killer activity of tumor-infiltrating lymphocytes in aging rats.
    Ziółkowska M; Nowak JJ; Janiak M; Ryzewska A
    Arch Immunol Ther Exp (Warsz); 1993; 41(5-6):357-64. PubMed ID: 8010877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.
    Forni G; Giovarelli M
    J Immunol; 1984 Jan; 132(1):527-33. PubMed ID: 6228583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of TCGF (T-cell growth factor) on experimental malignant glioma-specific killer T-cell].
    Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
    No Shinkei Geka; 1984 Feb; 12(2):141-50. PubMed ID: 6609319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
    Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
    Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose response and growth rates of subcutaneous tumors induced with 3-methylcholanthrene in mice and timing of tumor origin.
    Tanooka H; Tanaka K; Arimoto H
    Cancer Res; 1982 Nov; 42(11):4740-3. PubMed ID: 7127309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapeutic effect of allogeneic tumor cells on the growth of autochthonous 3-methylcholanthrene-induced sarcomas in rats.
    Kudo H; Suga M; Ogasawara M; Sato T; Usubuchi I
    Tohoku J Exp Med; 1979 Apr; 127(4):353-8. PubMed ID: 442081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
    Haranaka K; Sakurai A; Satomi N
    J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
    Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
    Cancer Res; 1999 Jun; 59(12):2950-6. PubMed ID: 10383160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyltransferase acceptor.
    Podolsky DK; Carter EA; Isselbacher KJ
    Cancer Res; 1983 Sep; 43(9):4026-30. PubMed ID: 6409394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice.
    Vaage J
    Cancer Res; 1972 Feb; 32(2):193-9. PubMed ID: 5058179
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice.
    Fu Q; Meng F; Shen X; Guo R
    Chin Med J (Engl); 2003 Feb; 116(2):288-91. PubMed ID: 12775249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-2 gene therapy of surgical minimal residual tumour disease.
    Vlk V; Rössner P; Indrová M; Bubeník J; Sobota V
    Int J Cancer; 1998 Mar; 76(1):115-9. PubMed ID: 9533770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood flow-interrupting hyperthermic chemotherapy on established autochthonous mouse sarcoma induced by 3-methylcholanthrene.
    Kidera Y; Baba T
    Cancer Res; 1978 Mar; 38(3):556-9. PubMed ID: 626960
    [No Abstract]   [Full Text] [Related]  

  • 59. BCG immunotherapy of a rat sarcoma.
    Baldwin RW; Pimm MV
    Br J Cancer; 1973 Oct; 28(4):281-7. PubMed ID: 4759936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intralesional immunotherapy of brain tumors with combined Corynebacterium parvum and recombinant interleukin-2 in mice.
    Conley FK; Adler JR; Duncan JA; Kennedy JD; Sutton RC
    J Natl Cancer Inst; 1990 Aug; 82(16):1340-4. PubMed ID: 2380991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.